|
Dr. Zankel is a co-founder and the Chief Scientific Officer of Raptor. From 1997 to 2005 Dr. Zankel served as a Senior Director of Research at BioMarin Pharmaceutical Inc. Dr. Zankel’s research team developed highly productive manufacturing cell lines for BioMarin’s enzyme replacement drugs and protein drug candidates utilizing both bacterial and mammalian expression systems. Dr. Zankel’s research team created novel drugs production methods and drug-delivery technologies using both protein engineering and chemical approaches. Dr. Zankel’s team also supported the regulatory group at BioMarin by characterizing cell lines and developing documentation for two biologics license applications with the FDA. Additionally Dr. Zankel coordinated the activities of the process development and analytical groups for the NeuroTrans program currently under development at Raptor. At BioMarin Dr. Zankel also conceived and led the development of additional RAP-based technologies currently owned by Raptor.
Prior to 1997 Dr. Zankel was a National Institutes of Health postdoctoral fellow at the Plant Gene Expression Center in Berkeley California and at the Swiss Institute of Technology in Zurich Switzerland. Dr. Zankel has been the author of a number of peer-reviewed articles in a variety of scientific areas. Dr. Zankel earned a B.A. in Chemistry from Reed College in Portland Oregon and a Ph.D. in Chemistry from Columbia University. | 